Dr Reddy’s Laboratories has launched rivastigmine tartrate Capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of Exelon capsules in the US market on September 15, 2011 following the approval by the United States Food & Drug Administration (USFDA) of the company’s Abbreviated New Drug Application (ANDA) for rivastigmine tartrate capsules.
The Exelon brand and generic rivastigmine tartrate had US sales of about $92.6 million for the most recent twelve months ending June 2011. Dr Reddy’s rivastigmine tartrate capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg strengths are available in 60 count bottles.
Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1874.70 |
| Dr. Reddys Labs. | 1328.35 |
| Cipla | 1437.35 |
| Zydus Lifesciences | 1099.10 |
| Lupin | 2367.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: